The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function

AIMS: To assess whether hepatic impairment influences the pharmacokinetics of ziprasidone. METHODS: Thirty subjects with normal hepatic function or a primary diagnosis of clinically significant cirrhosis (Child-Pugh A or B) were enrolled into an open-label, multicentre, multiple-dose study. The subj...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Everson, G, Lasseter, K C, Anderson, K E, Bauer, L A, Carithens, R L, Wilner, K D, Johnson, A, Anziano, R J, Smolarek, T A, Turncliff, R Z
Formato: Artigo
Lenguaje:Inglês
Publicado: Blackwell Science Inc 2000
Materias:
Supplement
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2015053/
https://ncbi.nlm.nih.gov/pubmed/10771450
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1046/j.1365-2125.2000.00149.x
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares